Correlation between the international consensus definition of the Cancer Anorexia-Cachexia Syndrome (CACS) and patient-centered outcomes in advanced non-small cell lung cancer

Journal of Pain and Symptom Management

Volumn 49, Issue 4, 2015, Pages 680-689

  Leblanc, Thomas W ^a,b,c   Nipp, Ryan D ^d   Rushing, Christel N ^b   Samsa, Greg P ^b   Locke, Susan C ^b   Kamal, Arif H ^a,b,c   Cella, David F ^e   Abernethy, Amy P ^a,b,c  

^a DUKE CANCER INSTITUTE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

carcinoma; health services research; non small cell lung; Patient outcome assessment

Indexed keywords

ADVANCED CANCER; AGED; ARTICLE; ASSESSMENT OF HUMANS; CANCER ANOREXIA CACHEXIA SYNDROME; CANCER SURVIVAL; CONSENSUS; CONTROLLED STUDY; CORRELATIONAL STUDY; EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS SCORE; FEMALE; FUNCTIONAL ASSESSMENT OF ANOREXIA CACHEXIA TREATMENT; FUNCTIONAL ASSESSMENT OF CANCER THERAPY GENERAL LUNG CANCER SUBSCALE; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE SUBSCALE; HUMAN; KARNOFSKY PERFORMANCE STATUS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT CARE; WASTING SYNDROME; WEIGHT; ANOREXIA; BODY WEIGHT; CACHEXIA; CARCINOMA, NON-SMALL-CELL LUNG; INTERNATIONAL COOPERATION; MIDDLE AGED; NOMENCLATURE; PATHOPHYSIOLOGY; PROGNOSIS; QUALITY OF LIFE; SURVIVAL; SYNDROME;

AGED; ANOREXIA; BODY WEIGHT; CACHEXIA; CARCINOMA, NON-SMALL-CELL LUNG; CONSENSUS; FEMALE; HUMANS; INTERNATIONALITY; KARNOFSKY PERFORMANCE STATUS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; PROGNOSIS; QUALITY OF LIFE; SURVIVAL ANALYSIS; SYNDROME; TERMINOLOGY AS TOPIC;

EID: 84925936971     PISSN: 08853924     EISSN: 18736513     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2014.09.008     Document Type: Article

References (48)

1. W.J. Evans, J.E. Morley, and J. Argiles Cachexia: a new definition Clin Nutr 27 2008 793 799
2. J.M. Argiles, S.H. Meijsing, J. Pallares-Trujillo, X. Guirao, and F.J. Lopez-Soriano Cancer cachexia: a therapeutic approach Med Res Rev 21 2001 83 101
3. M. Couch, V. Lai, and T. Cannon Cancer cachexia syndrome in head and neck cancer patients: part I. Diagnosis, impact on quality of life and survival, and treatment Head Neck 29 2007 401 411
4. J. George, T. Cannon, and V. Lai Cancer cachexia syndrome in head and neck cancer patients: part II. Pathophysiology Head Neck 29 2007 497 507
5. K.C. Fearon, A.C. Voss, D.S. Hustead Cancer Cachexia Study Group Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis Am J Clin Nutr 83 2006 1345 1350
6. N. MacDonald, A.M. Easson, V.C. Mazurak, G.P. Dunn, and V.E. Baracos Understanding and managing cancer cachexia J Am Coll Surg 197 2003 143 161
7. M. Muscaritoli, M. Bossola, Z. Aversa, R. Bellantone, and F. Rossi Fanelli Prevention and treatment of cancer cachexia: new insights into an old problem Eur J Cancer 42 2006 31 41
8. B.H. Tan, and K.C. Fearon Cachexia: prevalence and impact in medicine Curr Opin Clin Nutr Metab Care 11 2008 400 407
9. M. Heckmayr, and U. Gatzemeier Treatment of cancer weight loss in patients with advanced lung cancer Oncology 49 Suppl 2 1992 32 34
10. I. Gioulbasanis, V.E. Baracos, and Z. Giannousi Baseline nutritional evaluation in metastatic lung cancer patients: Mini Nutritional Assessment versus weight loss history Ann Oncol 22 2011 835 841
11. K. Sanchez-Lara, J.G. Turcott, and E. Juarez Association of nutrition parameters including bioelectrical impedance and systemic inflammatory response with quality of life and prognosis in patients with advanced non-small-cell lung cancer: a prospective study Nutr Cancer 64 2012 526 534
12. B.S. van der Meij, C.P. Schoonbeek, and E.F. Smit Pre-cachexia and cachexia at diagnosis of stage III non-small-cell lung carcinoma: an exploratory study comparing two consensus-based frameworks Br J Nutr 109 2013 2231 2239
13. M. Bossola, F. Pacelli, A. Tortorelli, and G.B. Doglietto Cancer cachexia: it's time for more clinical trials Ann Surg Oncol 14 2007 276 285
14. O. Wallengren, K. Lundholm, and I. Bosaeus Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients Support Care Cancer 21 2013 1569 1577
15. M. Muscaritoli, S.D. Anker, and J. Argiles Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics" Clin Nutr 29 2010 154 159
16. A.S. Dobs, R.V. Boccia, and C.C. Croot Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial Lancet Oncol 14 2013 335 345
17. C.M. Prado, M.B. Sawyer, and S. Ghosh Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential? Am J Clin Nutr 98 2013 1012 1019
18. K. Fearon, F. Strasser, and S.D. Anker Definition and classification of cancer cachexia: an international consensus Lancet Oncol 12 2011 489 495
19. E. Del Fabbro, R. Dev, D. Hui, L. Palmer, and E. Bruera Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial J Clin Oncol 31 2013 1271 1276
20. J.M. Garcia, J. Friend, and S. Allen Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study Support Care Cancer 21 2013 129 137
21. C. Madeddu, M. Dessi, and F. Panzone Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib +/- megestrol acetate for patients with cancer-related anorexia/cachexia syndrome Clin Nutr 31 2012 176 182
22. S. Yennurajalingam, J.S. Willey, and J.L. Palmer The role of thalidomide and placebo for the treatment of cancer-related anorexia-cachexia symptoms: results of a double-blind placebo-controlled randomized study J Palliat Med 15 2012 1059 1064
23. D.A. Karnofsky, and J.H. Burchenal The clinical evaluation of chemotherapeutic agents in cancer C.M. MacLeod, Symposium on the Evaluation of Chemotherapeutic Agents 1949 Columbia University Press New York 191 205
24. M.M. Oken, R.H. Creech, and D.C. Tormey Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 1982 649 655
25. D.A. Kallman, C.C. Plato, and J.D. Tobin The role of muscle loss in the age-related decline of grip strength: cross-sectional and longitudinal perspectives J Gerontol 45 1990 M82 M88
26. D. Brooks, and S. Solway ATS statement on six-minute walk test Am J Respir Crit Care Med 167 2003 1287
27. A.P. Abernethy, J.E. Herndon 2nd, and J.L. Wheeler Feasibility and acceptability to patients of a longitudinal system for evaluating cancer-related symptoms and quality of life: pilot study of an e/tablet data-collection system in academic oncology J Pain Symptom Manage 37 2009 1027 1038
28. A.P. Abernethy, J.E. Herndon 2nd, and J.L. Wheeler Improving health care efficiency and quality using tablet personal computers to collect research-quality, patient-reported data Health Serv Res 43 2008 1975 1991
29. A.P. Abernethy, S.Y. Zafar, and H. Uronis Validation of the Patient Care Monitor (Version 2.0): a review of system assessment instrument for cancer patients J Pain Symptom Manage 40 2010 545 558
30. A. Cnaan, N.M. Laird, and P. Slasor Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data Stat Med 16 1997 2349 2380
31. S. Fielding, P.M. Fayers, J.H. Loge, M.S. Jordhoy, and S. Kaasa Methods for handling missing data in palliative care research Palliat Med 20 2006 791 798
32. B.F. Kurland, L.L. Johnson, and P.H. Diehr Accommodation of missing data in supportive and palliative care clinical trials Curr Opin Support Palliat Care 6 2012 465 470
33. J.A. Sterne, I.R. White, and J.B. Carlin Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls BMJ 338 2009 b2393
34. P.S. Brucker, K. Yost, J. Cashy, K. Webster, and D. Cella General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G) Eval Health Prof 28 2005 192 211
35. D. Cella, D.T. Eton, and D.L. Fairclough What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire?: results from Eastern Cooperative Oncology Group (ECOG) Study 5592 J Clin Epidemiol 55 2002 285 295
36. D. Cella, D.T. Eton, J.S. Lai, A.H. Peterman, and D.E. Merkel Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales J Pain Symptom Manage 24 2002 547 561
37. V.E. Baracos, T. Reiman, M. Mourtzakis, I. Gioulbasanis, and S. Antoun Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis Am J Clin Nutr 91 2010 1133S 1137S
38. M. Mourtzakis, C.M. Prado, and J.R. Lieffers A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care Appl Physiol Nutr Metab 33 2008 997 1006
39. S. Antoun, V.E. Baracos, L. Birdsell, B. Escudier, and M.B. Sawyer Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma Ann Oncol 21 2010 1594 1598
40. C.M. Prado, V.E. Baracos, and L.J. McCargar Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment Clin Cancer Res 15 2009 2920 2926
41. B.H. Tan, L.A. Birdsell, L. Martin, V.E. Baracos, and K.C. Fearon Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer Clin Cancer Res 15 2009 6973 6979
42. D.C. McMillan An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer Proc Nutr Soc 67 2008 257 262
43. K. Fearon, J. Arends, and V. Baracos Understanding the mechanisms and treatment options in cancer cachexia Nat Rev Clin Oncol 10 2013 90 99
44. K.C. Fearon Cancer cachexia: developing multimodal therapy for a multidimensional problem Eur J Cancer 44 2008 1124 1132
45. D.F. Cella, D.S. Tulsky, and G. Gray The Functional Assessment of Cancer Therapy scale: development and validation of the general measure J Clin Oncol 11 1993 570 579
46. D.F. Cella, A.E. Bonomi, and S.R. Lloyd Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument Lung Cancer 12 1995 199 220
47. J. Ribaudo, D. Cella, and A. Hahn Re-validation and shortening of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire Qual Life Res 9 2000 1137 1146
48. S.B. Yellen, D.F. Cella, K. Webster, C. Blendowski, and E. Kaplan Measuring fatigue and other anemia related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system J Pain Symptom Manage 13 1997 63 74